Literature DB >> 29731835

Effect of miR-146a-5p on proliferation and metastasis of triple-negative breast cancer via regulation of SOX5.

Chengshuai Si1, Qiao Yu1, Yufeng Yao1.   

Abstract

MicroRNA (miR)-146a-5p functions as a tumor suppressor in various types of cancer. However, the role of miR-146a-5p in the development of triple-negative breast cancer (TNBC) is unclear. The present study aimed to investigate the role of miR-146a-5p in TNBC. The expression level of miR-146a-5p in TNBC tissues and cell lines was initially detected using reverse transcription-quantitative polymerase chain reaction. To predict the target gene of miR-146a-5p, TargetScan software was used and a dual luciferase assay was performed to verify the prediction. Furthermore, in order to explore the role of miR-146a-5p in TNBC, miR-146a-5p was overexpressed in TNBC cells using miR-146a-5p mimics. An MTT assay was performed to detect cell proliferation, and a Transwell assay was conducted to determine cell migration and invasion. Furthermore, western blotting was performed to measure associated protein expression. It was revealed that miR-146a-5p was downregulated in TNBC tissues and cell lines. SOX5 was indicated to be a target gene of miR-146a-5p and was upregulated in TNBC cells. Additionally, miR-146a-5p could inhibit TNBC cell proliferation, migration and invasion, repress the expression of mesenchymal markers (N-cadherin, vimentin and fibronectin) and increase epithelial marker (E-cadherin) expression. Furthermore, SOX5 overexpression eliminated the effects of miR-146a-5p mimics on TNBC cells. In conclusion, the data of the present study indicated that miR-146a-5p inhibits the proliferation and metastasis of TNBC cells by regulating SOX5.

Entities:  

Keywords:  SOX5; cell proliferation; metastasis; microRNA-146a-5p; triple-negative breast cancer

Year:  2018        PMID: 29731835      PMCID: PMC5920859          DOI: 10.3892/etm.2018.5945

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  34 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  The widespread regulation of microRNA biogenesis, function and decay.

Authors:  Jacek Krol; Inga Loedige; Witold Filipowicz
Journal:  Nat Rev Genet       Date:  2010-07-27       Impact factor: 53.242

3.  Combining miR-10b-Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer.

Authors:  Byunghee Yoo; Amol Kavishwar; Alana Ross; Ping Wang; Doris P Tabassum; Kornelia Polyak; Natalia Barteneva; Victoria Petkova; Pamela Pantazopoulos; Aseda Tena; Anna Moore; Zdravka Medarova
Journal:  Cancer Res       Date:  2015-09-10       Impact factor: 12.701

4.  Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Authors:  A S Coates; E P Winer; A Goldhirsch; R D Gelber; M Gnant; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2015-05-04       Impact factor: 32.976

5.  miR-181b-3p promotes epithelial-mesenchymal transition in breast cancer cells through Snail stabilization by directly targeting YWHAG.

Authors:  Je-Ok Yoo; Seo-Young Kwak; Hyun-Ju An; In-Hwa Bae; Myung-Jin Park; Young-Hoon Han
Journal:  Biochim Biophys Acta       Date:  2016-04-18

6.  miR-490-3p inhibits the growth and invasiveness in triple-negative breast cancer by repressing the expression of TNKS2.

Authors:  Zhongming Jia; Yan Liu; Qiang Gao; Yong Han; Guoqiang Zhang; Shujian Xu; Kai Cheng; Weiwei Zou
Journal:  Gene       Date:  2016-08-06       Impact factor: 3.688

7.  Circulating MiR-125b as a marker predicting chemoresistance in breast cancer.

Authors:  Hongjiang Wang; Guang Tan; Lei Dong; Lei Cheng; Kejun Li; Zhongyu Wang; Haifeng Luo
Journal:  PLoS One       Date:  2012-04-16       Impact factor: 3.240

8.  Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.

Authors:  Sul Ki Choi; Hoe Suk Kim; Tiefeng Jin; Eun Hye Hwang; Minji Jung; Woo Kyung Moon
Journal:  BMC Cancer       Date:  2016-08-02       Impact factor: 4.430

9.  ANXA1 inhibits miRNA-196a in a negative feedback loop through NF-kB and c-Myc to reduce breast cancer proliferation.

Authors:  Yi Yuan; Durkeshwari Anbalagan; Lay Hoon Lee; Ramar Perumal Samy; Muthu K Shanmugam; Alan Prem Kumar; Gautam Sethi; Peter E Lobie; Lina H K Lim
Journal:  Oncotarget       Date:  2016-05-10

10.  MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.

Authors:  Liang-Liang Chen; Zhou-Jing Zhang; Zhan-Bo Yi; Jian-Jun Li
Journal:  Br J Cancer       Date:  2017-06-01       Impact factor: 7.640

View more
  15 in total

Review 1.  Emerging Role of SOX Proteins in Breast Cancer Development and Maintenance.

Authors:  Gaurav A Mehta; Pooja Khanna; Michael L Gatza
Journal:  J Mammary Gland Biol Neoplasia       Date:  2019-05-09       Impact factor: 2.673

2.  miR-522 regulates cell proliferation, migration, invasion capacities and acts as a potential biomarker to predict prognosis in triple-negative breast cancer.

Authors:  Wei Wang; Wei Zhang; Jianhua Wu; Zhuchao Zhou; Jinglin Ma
Journal:  Clin Exp Med       Date:  2021-09-14       Impact factor: 5.057

3.  Systematic identification of the cancer pathways and molecules related with breast cancer immunogenicity.

Authors:  Xiaoli Wang; Silu Xu; Lingli Huang; Lei Wang; Nan Wu
Journal:  Med Oncol       Date:  2021-06-04       Impact factor: 3.064

4.  Research on correlations of miR-585 expression with progression and prognosis of triple-negative breast cancer.

Authors:  Minya Yao; Shuqian Wang; Luyan Chen; Bajin Wei; Peifen Fu
Journal:  Clin Exp Med       Date:  2021-04-07       Impact factor: 3.984

Review 5.  MicroRNAs Involved in Carcinogenesis, Prognosis, Therapeutic Resistance and Applications in Human Triple-Negative Breast Cancer.

Authors:  Lei Ding; Huan Gu; Xianhui Xiong; Hongshun Ao; Jiaqi Cao; Wen Lin; Min Yu; Jie Lin; Qinghua Cui
Journal:  Cells       Date:  2019-11-22       Impact factor: 6.600

6.  Reporting on the Role of miRNAs and Affected Pathways on the Molecular Backbone of Ovarian Insufficiency: A Systematic Review and Critical Analysis Mapping of Future Research.

Authors:  Anna Rapani; Dimitra Nikiforaki; Dimitra Karagkouni; Konstantinos Sfakianoudis; Petroula Tsioulou; Sokratis Grigoriadis; Evangelos Maziotis; Amelia Pantou; Aikaterini Voutsina; Agni Pantou; Michael Koutsilieris; Artemis Hatzigeorgiou; Konstantinos Pantos; Mara Simopoulou
Journal:  Front Cell Dev Biol       Date:  2021-01-12

7.  MicroRNA panel in serum reveals novel diagnostic biomarkers for prostate cancer.

Authors:  Shiyu Zhang; Cheng Liu; Xuan Zou; Xiangnan Geng; Xin Zhou; XingChen Fan; Danxia Zhu; Huo Zhang; Wei Zhu
Journal:  PeerJ       Date:  2021-05-19       Impact factor: 2.984

8.  Overexpression of MiR-146a-5p Upregulates lncRNA HOTAIR in Triple-Negative Breast Cancer Cells and Predicts Poor Prognosis.

Authors:  Hongguang Liang; Weihua Huang; Yuandong Wang; Lingying Ding; Lixian Zeng
Journal:  Technol Cancer Res Treat       Date:  2019 Jan-Dec

9.  Hypoxia Activates SOX5/Wnt/β-Catenin Signaling by Suppressing MiR-338-3p in Gastric Cancer.

Authors:  Jing-Jing Zheng; Qiao-Yan Que; Hong-Tao Xu; de-Sheng Luo; Zheng Sun; Jun-Sheng Ni; Hai-Feng Que; Ji Ma; Dan Wu; Hua Shi
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

10.  MicroRNA-146a suppresses tumor malignancy via targeting vimentin in esophageal squamous cell carcinoma cells with lower fibronectin membrane assembly.

Authors:  Hong-Yi Chang; Chi-Hua Lee; Yi-Syuan Li; Jing-Tong Huang; Sheng-Hui Lan; Yi-Fang Wang; Wu-Wei Lai; Yi-Ching Wang; Yan-Ju Lin; Hsiao-Sheng Liu; Hung-Chi Cheng
Journal:  J Biomed Sci       Date:  2020-11-28       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.